Familial Hemophagocytic Lymphohistiocytosis

Hematology/Oncology Clinics of North America

Volumn 29, Issue 5, 2015, Pages 903-913

  Degar, Barbara ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Familial hemophagocytic lymphohistiocytosis; FHL; Hemophagocytic lymphohistiocytosis; HLH; Perforin; XLP

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; ETOPOSIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; THYMOCYTE ANTIBODY;

FLOW CYTOMETRY; GENE MUTATION; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; MOLECULAR DIAGNOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; GENETIC PREDISPOSITION; GENETIC VARIATION; INCIDENCE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MULTIMODALITY CANCER THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INCIDENCE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; TREATMENT OUTCOME;

EID: 84942365449     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.06.008     Document Type: Review

References (43)

1. Meeths M., Horne A., Sabel M., et al. Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatr Blood Cancer 2015, 62:346-352.
2. Ishii E., Ohga S., Imashuku S., et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007, 86(1):58-65.
3. Farquhar J.W., Claireaux A.E. Familial haemophagocytic reticulosis. Arch Dis Child 1952, 27(136):519-525.
4. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999, 286(5446):1957-1959.
5. Ohadi M., Lalloz M.R., Sham P., et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 1999, 64(1):165-171.
6. Jordan M.B., Filipovich A.H. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant 2008, 42(7):433-437.
7. Trizzino A., Zur Stadt U., Ueda I., et al. Genotype-phenotype study of familial hemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet 2007, 45(1):15-21.
8. Lee S.M., Sumegi J., Villanueva J., et al. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J Pediatr 2006, 149(1):134-137.
9. Feldmann J., Callebaut I., Raposo G., et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL-3). Cell 2003, 115(4):461-473.
10. Sieni E., Cetica V., Santoro A., et al. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet 2011, 48(5):343-352.
11. Santoro A., Cannella S., Bossi G., et al. Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis. J Med Genet 2006, 43(12):953-960.
12. zur Stadt U., Schmidt S., Kasper B., et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005, 14(6):827-834.
13. Cote M., Ménager M.M., Burgess A., et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest 2009, 119(12):3765-3773.
14. Pagel J., Beutel K., Lehmberg K., et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Blood 2012, 119(25):6016-6024.
15. Nichols K.E., Harkin D.P., Levitz S., et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998, 95(23):13765-13770.
16. Rigaud S., Fondanèche M.C., Lambert N., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444(7115):110-114.
17. Marsh R.A., Madden L., Kitchen B.J., et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010, 116(7):1079-1082.
18. Pachlopnik Schmid J., Canioni D., Moshous D., et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011, 117(5):1522-1529.
19. Menasche G., Pastural E., Feldmann J., et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000, 25(2):173-176.
20. Meeths M., Bryceson Y.T., Rudd E., et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer 2010, 54(4):563-572.
21. Zhang K., Jordan M.B., Marsh R.A., et al. Hypomorphic mutations in PRF1, Munc13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 2011, 118(22):5794-5798.
22. Spessott W.A., Sanmillan M.L., McCormick M.E., et al. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood 2015, 125(10):1566-1577.
23. Zhang K., Chandrakasan S., Chapman H., et al. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 2014, 124(8):1331-1334.
24. Kaufman K.M., Linghu B., Szustakowski J.D., et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2014, 66(12):3486-3495.
25. Henter J.I., Elinder G., Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 1991, 18(1):29-33.
26. Henter J.I., Horne A., Aricó M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48(2):124-131.
27. Perez N., Virelizier J.L., Arenzana-Seisdedos F., et al. Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr 1984, 104(4):569-573.
28. Ishii E., Ueda I., Shirakawa R., et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood 2005, 105(9):3442-3448.
29. Marcenaro S., Gallo F., Martini S., et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 2006, 108(7):2316-2323.
30. Bryceson Y.T., Pende D., Maul-Pavicic A., et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012, 119(12):2754-2763.
31. Janka G.E. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983, 140(3):221-230.
32. Ambruso D.R., Hays T., Zwartjes W.J., et al. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer 1980, 45(10):2516-2520.
33. Johnson T.S., Terrell C.E., Millen S.H., et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 2014, 192(1):84-91.
34. Henter J.I., Samuelsson-Horne A., Aricò M., et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002, 100(7):2367-2373.
35. Mahlaoui N., Ouachée-Chardin M., de Saint Basile G., et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 2007, 120(3):e622-e628.
36. Marsh R.A., Allen C.E., McClain K.L., et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013, 60(1):101-109.
37. Horne A., Trottestam H., Aricò M., et al. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 2008, 140(3):327-335.
38. Haddad E., Sulis M.L., Jabado N., et al. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 1997, 89(3):794-800.
39. Baker K.S., Filipovich A.H., Gross T.G., et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 2008, 42(3):175-180.
40. Fischer A., Cerf-Bensussan N., Blanche S., et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr 1986, 108(2):267-270.
41. Trottestam H., Horne A., Aricò M., et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011, 118(17):4577-4584.
42. Cooper N., Rao K., Gilmour K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 2006, 107(3):1233-1236.
43. Marsh R.A., Vaughn G., Kim M.O., et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 2010, 116(26):5824-5831.